During the last session, Traws Pharma Inc (NASDAQ:TRAW)’s traded shares were 0.32 million, with the beta value of the company hitting 1.20. At the end of the trading day, the stock’s price was $1.42, reflecting an intraday gain of 2.16% or $0.03. The 52-week high for the TRAW share is $19.44, that puts it down -1269.01 from that peak though still a striking 31.69% gain since the share price plummeted to a 52-week low of $0.97. The company’s market capitalization is $7.90M, and the average trade volume was 117.53K shares over the past three months.

Traws Pharma Inc (NASDAQ:TRAW) trade information

Traws Pharma Inc (TRAW) registered a 2.16% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.16% in intraday trading to $1.42, hitting a weekly high. The stock’s 5-day price performance is 12.70%, and it has moved by -2.07% in 30 days. Based on these gigs, the overall price performance for the year is -90.60%.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 42.51%.

TRAW Dividends

Traws Pharma Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Also, the Mutual Funds coming in first place with the largest holdings of Traws Pharma Inc (TRAW) shares are Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Mar 31, 2025 indicates that Fidelity Concord Street Trust-Fidelity Extended Market Index Fund owns about 17.01 shares. This amounts to just over 0.31 percent of the company’s overall shares, with a $24155.0 market value. The same data shows that the other fund manager holds slightly less at 12.91, or about 0.23% of the stock, which is worth about $18333.0.